This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 1 of 240 for:    CHIARA
Previous Study | Return to List | Next Study

A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) (CHIARA)

This study has been completed.
Information provided by (Responsible Party):
Synta Pharmaceuticals Corp. Identifier:
First received: March 14, 2012
Last updated: May 18, 2015
Last verified: May 2015
Phase 2 study of subjects with ALK positive, advanced NSCLC who have failed up to 3 prior therapies. The study will take place globally at multiple study centers. Subjects will be enrolled to receive ganetespib one time per week for three weeks followed by a rest week; and will repeat this schedule until the cancer gets worse or the subject is unable to tolerate ganetespib. The primary goal of the study is to determine how ganetespib is tolerated and how active it is in ALK positive NSCLC.

Condition Intervention Phase
Non Small Cell Lung Cancer Drug: Ganetespib Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Single Arm, Phase 2 Study of Ganetespib in Subjects With Advanced Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Gene Rearrangement (ALK-Positive NSCLC)

Resource links provided by NLM:

Further study details as provided by Synta Pharmaceuticals Corp.:

Primary Outcome Measures:
  • Objective response rate [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Duration of Response [ Time Frame: 1 year ]
  • Disease Control Rate [ Time Frame: 6 weeks and 12 weeks ]
  • Adverse events [ Time Frame: 1 year ]
  • Progression Free Survival [ Time Frame: From the date of study drug start until the date of first documented progression or date of death from any cause, whichever comes frist, assessed up to 3 years ]
  • Overall Survival [ Time Frame: 1 year ]

Enrollment: 12
Study Start Date: April 2012
Study Completion Date: November 2014
Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ganetespib
Ganetespib IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
Drug: Ganetespib
Ganetespib 200 mg/m2 administered 1 time per week for the first three weeks of a four week treatment cycle (Days 1, 8, and 15 of the 28 Day treatment cycle).


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males or females aged 18 years or older
  • Pathological confirmation of advanced NSCLC
  • Evidence of a translocation or an inversion event involving the ALK gene locus
  • ECOG Performance Status 0 or 1

Exclusion Criteria:

  • Prior therapy with ALK-targeted agents
  • Prior treatment with Hsp90 inhibitor
  • Known EGFR activating mutation
  • Presence of active or untreated central nervous system (CNS) metastases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01562015

United States, Florida
Synta Pharmaceuticals Investigative Site
Tampa, Florida, United States, 33612
United States, Ohio
Synta Pharmaceuticals Investigative Site
Cleveland, Ohio, United States, 44195
Canada, Ontario
Synta Pharmaceuticals Investigative Site
Hamilton, Ontario, Canada, ON L8V 5C2
Synta Pharmaceuticals Investigative Site
Ottawa, Ontario, Canada, K1H 8L6
Synta Pharmaceuticals Investigative Site
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
Synta Pharmaceuticals Corp.
  More Information

Responsible Party: Synta Pharmaceuticals Corp. Identifier: NCT01562015     History of Changes
Other Study ID Numbers: 9090-09
Study First Received: March 14, 2012
Last Updated: May 18, 2015

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms processed this record on August 16, 2017